Why Anacor Pharmaceuticals Inc. Stock Briefly Dipped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Anacor Pharmaceuticals (NASDAQ: ANAC  ) , a biopharmaceutical company focused on developing anti-fungal and anti-inflammatory medications, briefly dipped as much as 11% this morning following the Food and Drug Administration's approval of Kerydin as a treatment for onychomycosis of the toenails. Shares have since recovered and are now down just 1% as of this writing.

So what?: According to Anacor's early morning press release, the FDA has approved its topical solution known as Kerydin to treat a fungal infection of the toenail and nail bed that's found in approximately 35 million people in the U.S. According to Anacor's CEO Paul Berns "We expect to launch KERYDIN in the U.S., either alone or with a partner, as early as the end of this quarter." Based on a previous investor presentation from Anacor, the company believes Kerydin could have peak sales potential of beyond $1 billion.

Now what?: Normally we see a company move higher on an FDA approval, but two factors appear to be playing into today's drop. First, Anacor has rocketed higher in anticipation of this approval with shares rising from just $6 to yesterday's closing price of $16.74. In other words, it's not as if the market hasn't already factored in some of the optimism surrounding Kerydin. The other factor at work here is Berns' commentary about finding a partner. I suspect some investors are disappointed that the smaller Anacor has yet to find an established partner for its drug and they're worried about launch and execution risk. Personally, I'm excited for Anacor and its shareholders, but I share both of these aforementioned concerns. I'd stick to the sidelines and wait for Anacor to get a few quarters of sales under its belt before even considering the idea of chasing this stock any higher.

Kerydin may have plenty of potential, but this revolutionary product may leave it in the dust!  
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3021608, ~/Articles/ArticleHandler.aspx, 11/26/2014 9:51:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement